Work

A phase I dose-defining study for MK-2206 combined with gefitinib in NSCLC population enriched with EGFR mutation.

Year: 2014

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2014.32.15_suppl.e19013

Authors: Chia-Chi Lin, Chong-Jen Yu, Chao-Chi Ho, Kuan-Yu Chen, Jin-Yuan Shih, Zhong-Zhe Lin, Yu-lin Lin, Wei-Yu Liao, Shoung-Hui Tsai, Li Yan, James Chih-Hsin Yang

Institution: National Taiwan University Hospital

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2603547023

Cites:

Cited by: 3

Related to: 10